Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched
MA Holder Theramex Has Plans For More EU Countries
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
You may also be interested in...
Women’s health specialist Theramex has struck a deal with Alkem’s Enzene Biosciences biotech subsidiary to gain rights to Enzene’s proposed denosumab biosimilar version of Prolia in Europe and Australia.
Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.
Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.